Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Indacaterol 150 μg
Drug: Tiotropium 18 μg
Drug: Placebo

First Posted Date: 2009-10-22

Last Posted Date: 2016-02-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT00999908

Locations: 🇮🇹
Novartis Investigative Site, Verona, Italy

Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics

Phase 4

Withdrawn

Conditions: Asthma

Interventions: Drug: Foradil Combi (Formoterol-budesonide)

First Posted Date: 2009-10-19

Last Posted Date: 2017-04-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00997477

Locations: 🇹🇷
Novarits Investigator Site, Istanbul, Turkey
🇹🇷
Novartis Investigator Site, Izmir, Turkey

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: panobinostat (LBH589)

First Posted Date: 2009-10-19

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT00997399

Locations: 🇺🇸
University of Utah / Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇬🇧
Novartis Investigative Site, Merseyside, United Kingdom

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2
Prediabetic State
Atherosclerosis

Interventions: Drug: Placebo
Drug: ACZ885

First Posted Date: 2009-10-16

Last Posted Date: 2015-06-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 189

Registration Number: NCT00995930

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Phase III Study in Refractory Behcet's Disease

Phase 3

Completed

Conditions: Behcet Disease

Interventions: Drug: AIN457
Drug: Placebo

First Posted Date: 2009-10-15

Last Posted Date: 2015-08-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 118

Registration Number: NCT00995709

Locations: 🇹🇷
Novartis Investigative Site, Izmir, Turkey

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Phase 3

Completed

Conditions: Cryopyrin-associated Periodic Syndromes
Muckle-Wells Syndrome
Neonatal Onset Multisystem Inflammatory Disease
Familial Cold Autoinflammatory Syndrome

Interventions: Drug: canakinumab

First Posted Date: 2009-10-07

Last Posted Date: 2020-09-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT00991146

Locations: 🇯🇵
Novartis Investigative Site, Kyoto-city, Kyoto, Japan

Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

Phase 2

Terminated

Conditions: Keloids

Interventions: Drug: QAX576 placebo
Drug: QAX576

First Posted Date: 2009-10-01

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT00987545

Locations: 🇺🇸
TKL Research, Inc, Paramus, New Jersey, United States
🇺🇸
Dermatology Consulting Services, High Point, North Carolina, United States
🇺🇸
Skin Search of Rochester/Dermatology Associates, Rochester, New York, United States

and more 1 locations

Safety and Efficacy of BFH772 in Psoriasis Patients

Phase 1

Completed

Conditions: Psoriasis
Arthritis

Interventions: Drug: BFH772
Drug: Placebo
Drug: calcipotriol/betamethasone

First Posted Date: 2009-10-01

Last Posted Date: 2011-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT00987870

Locations: 🇩🇪
Novartis Investigator Site, Berlin, Germany

Intra-venous Zoledronic Acid Once Yearly

Completed

Conditions: Post-Menopausal Osteoporosis

Interventions: Drug: Any oral bisphosphonates marketed in Canada
Drug: zoledronic acid

First Posted Date: 2009-09-25

Last Posted Date: 2016-03-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1551

Registration Number: NCT00984893

Locations: 🇨🇦
Groupe de recherche en rhumatologie et maladies osseuses Inc, Quebec, Canada

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Phase 2

Completed

Conditions: Chronic Hepatitis C Genotype-1 Relapse

Interventions: Drug: NIM811
Drug: Placebo BID + SOC

First Posted Date: 2009-09-23

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT00983060

Locations: 🇺🇸
Research and Education Inc., San Diego, California, United States
🇺🇸
University Hepatitis Center, Sarasota, Florida, United States
🇺🇸
Alamo Medical Research, San Antonio, Texas, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy